Mostrar el registro sencillo del ítem
dc.contributor.author
Leathers, James S.
dc.contributor.author
Balderramo, Domingo
dc.contributor.author
Prieto, John
dc.contributor.author
Diehl, Fernando
dc.contributor.author
Gonzalez Ballerga, Esteban
dc.contributor.author
Ferreiro, Melina R.
dc.contributor.author
Carrera, Enrique
dc.contributor.author
Barreyro, Fernando Javier
dc.contributor.author
Diaz-Ferrer, Javier
dc.contributor.author
Singh, Dupinder
dc.contributor.author
Mattos, Angelo Z.
dc.contributor.author
Carrilho, Flair
dc.contributor.author
Debes, Jose D.
dc.date.available
2019-10-01T14:03:43Z
dc.date.issued
2019-07
dc.identifier.citation
Leathers, James S.; Balderramo, Domingo; Prieto, John; Diehl, Fernando; Gonzalez Ballerga, Esteban; et al.; Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis from the South American Liver Research Network; Lippincott Williams; Journal Of Clinical Gastroenterology; 53; 6; 7-2019; 464-469
dc.identifier.issn
0192-0790
dc.identifier.uri
http://hdl.handle.net/11336/84889
dc.description.abstract
Goals:We aim to describe the efficacy, safety profile, and variables associated with survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib in South America.Background:Sorafenib has been shown to improve survival in patients with advanced HCC. There are few data on sorafenib use for HCC in South America.Study:We performed a retrospective analysis of HCC cases treated with sorafenib from 8 medical centers in 5 South American countries, between January 2010 and June 2017. The primary endpoint was overall survival (OS), which was defined as time from sorafenib initiation to death or last follow-up. Risk factors for decreased OS were assessed using Cox proportional hazard regression and log-rank tests.Results:Of 1336 evaluated patients, 127 were treated with sorafenib and were included in the study. The median age of individuals was 65 years (interquartile range, 55 to 71) and 70% were male individuals. Median OS in all patients was 8 months (interquartile range, 2 to 17). Variables associated with survival on multivariate analysis were platelets >/<250,000 mm3 (2 vs. 8 mo, P=0.01) and Barcelona Clinic Liver Cancer (BCLC) stage (A/B, 13 vs. C/D, 6 mo; P=0.04). In a subanalysis of patients with BCLC stage C, platelets >/<250,000 mm3 were also independently associated with survival (2 vs. 5.5 mo, P=0.03). Patients lived longer if they experienced any side effects from sorafenib use (11 vs. 2 mo, P=0.009). Patients who stopped sorafenib because of side effects had shorter survival compared with patients who were able to tolerate side effects and continue treatment (7.5 vs. 13 mo, P=0.01).Conclusions:Pretreatment elevation of platelets and advanced BCLC stage were independently associated with poor survival on sorafenib in a South American cohort.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Lippincott Williams
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
HEPATOCELLULAR CARCINOMA
dc.subject
SORAFENIB
dc.subject
SOUTH AMERICA
dc.subject
SURVIVAL
dc.subject.classification
Gastroenterología y Hepatología
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis from the South American Liver Research Network
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-09-27T15:01:43Z
dc.journal.volume
53
dc.journal.number
6
dc.journal.pagination
464-469
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Leathers, James S.. Vanderbilt University School Of Medicine; Estados Unidos
dc.description.fil
Fil: Balderramo, Domingo. Instituto Universitario de Ciencias Biomédicas de Córdoba; Argentina
dc.description.fil
Fil: Prieto, John. Centro de Enfermedades Hepáticas y Digestivas; Colombia
dc.description.fil
Fil: Diehl, Fernando. Instituto Universitario de Ciencias Biomédicas de Córdoba; Argentina
dc.description.fil
Fil: Gonzalez Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
dc.description.fil
Fil: Ferreiro, Melina R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
dc.description.fil
Fil: Carrera, Enrique. Hospital Eugenio Espejo; Ecuador
dc.description.fil
Fil: Barreyro, Fernando Javier. Universidad Nacional de Misiones; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
dc.description.fil
Fil: Diaz-Ferrer, Javier. Hospital Nacional Edgardo Rebagliati Martins; Perú
dc.description.fil
Fil: Singh, Dupinder. University of Minnesota; Estados Unidos
dc.description.fil
Fil: Mattos, Angelo Z.. Universidade Federal de Ciencias Da Saúde de Porto Alegre; Brasil
dc.description.fil
Fil: Carrilho, Flair. Universidade de Sao Paulo; Brasil
dc.description.fil
Fil: Debes, Jose D.. University of Minnesota; Estados Unidos
dc.journal.title
Journal Of Clinical Gastroenterology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/MCG.0000000000001085
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://insights.ovid.com/crossref?an=00004836-201907000-00017
Archivos asociados